Cooper Companies stock soars after strategic review announcement

Cooper Companies (NASDAQ: COO) jumped 11.3% after-hours after announcing a formal strategic review and reporting fiscal Q4 revenue of $1.07 billion (up 5% YoY, 3% organic) and non-GAAP diluted EPS of $1.15 versus $1.11 expected. Full-year fiscal 2025 revenue was $4.1 billion (up 5%) with non-GAAP EPS of $4.13 (up 12%), and management issued fiscal 2026 guidance of $4.30–4.34 billion revenue (4.5–5.5% organic growth), EPS $4.45–4.60 and free cash flow $575–625 million. The board also announced a chair succession to Colleen Jay effective Jan. 2, 2026, while the strategic review (including potential partnerships, divestitures or M&A) signals possible material capital allocation moves ahead.

Analysis

Market structure: Cooper’s (COO) strategic review and beat materially raise the probability of near-term M&A or carve-ups, directly benefiting acquirers with balance-sheet firepower (large med‑techs or PE) and shareholders if multiple expansion or asset sales occur; competitors with overlapping product lines (large ophthalmic/ women’s-health units at MDT/ALGN/BSX) face renewed consolidation risk and pricing pressure. A formal review that targets $575–625m FCF in FY26 signals ample internal liquidity to execute deals or return capital, tightening supply of standalone assets and increasing demand for mid‑cap med‑tech targets over 3–12 months.

Risk assessment: Tail risks include a failed strategic process (no bidders), regulatory blocks to cross‑border deals, or execution drift that erodes the current 11%+ pop; assign 10–20% probability to a disappointing outcome within 6–12 months that could reverse gains. Immediate volatility (days) will be driven by headlines (board filings, LOIs), short‑term (weeks/months) by bidder emergence and due diligence, long‑term (quarters/years) by realized asset dispositions and reinvestment of proceeds.

Trade implications: Favor idiosyncratic long exposure to COO sized to conviction (1–3% portfolio) and neutralize market beta via a medical‑device ETF hedge (IHI) to isolate deal upside; use 6–12 month call spreads to cap cost if implied vol rises post‑announcement. Rotate modestly into selective med‑tech midcaps that are likely consolidation targets and trim expensive growth tech exposure where M&A dollars may reallocate (reduce SMCI/APP exposure by 1–3%).

Contrarian angles: Consensus assumes breakup equals automatic value; history (Danaher, Abbott) shows timing, tax structure and buyer financing drive realized gains — if buyers demand discounts or regulatory divestitures, valuation could compress 10–25%. The market may be underpricing execution risk over the next 90–180 days; set clear exit triggers tied to concrete milestones (LOI, proxy, buyer announcement) to avoid an earnings‑beat fade scenario.

Key Decisions for Investors

• Establish a 1.5–3% long position in Cooper Companies (COO) within the next 1–4 weeks to capture potential rerating or transaction premium; set a hard stop at 8% below entry and a profit‑take zone of 12–20% within 3–9 months, or earlier on a confirmed LOI/transaction announcement.
• Implement a defined‑risk options trade: buy a 6–12 month COO call spread (buy near‑ATM call, sell 15–25% OTM call) sized to limit max loss to ~0.5–1% of portfolio; this captures upside from a successful strategic review while capping premium outlay if volatility spikes.
• Run a dollar‑neutral pair: long COO (2% portfolio) vs short IHI (iShares U.S. Medical Devices ETF) sized to neutralize beta, holding for 3–9 months to isolate idiosyncratic M&A upside; unwind if COO underperforms by >15% or if IHI outperforms by >10%.
• Trim 2–4% aggregate exposure to high‑multiple growth tech (examples: SMCI, APP) within 30 days and redeploy 50–75% of proceeds into mid‑cap med‑tech names with M&A appeal or into the COO position, prioritizing names with >$200m FCF and <15x EV/EBITDA.
• Set monitoring triggers: file/8‑K/13D alerts for COO and watch for LOI/proxy filings over the next 90 days; if a 13D or definitive agreement appears, increase position up to +2% incremental; if strategic review concludes with no action after 180 days, exit to avoid valuation fade.